Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 27
Encontrada(s) 1 página(s)

RUC. Repositorio da Universidade da Coruña
Publication Artículo científico (JournalArticle)

Targeted phospholipidomic analysis of synovial fluid as a tool for osteoarthritis deep phenotyping

  • Rocha Loureda, Beatriz
  • Illiano, Anna
  • Calamia, Valentina
  • Pinto, Gabriella
  • Amoresano, Angela
  • Ruiz-Romero, Cristina
  • Blanco García, Francisco J
[Abstract] Objective. The aim of this study was to carry out a targeted phospholipidomic analysis on synovial fluid (SF) from patients with different grades of osteoarthritis (OA) and controls, in order to search for specific phospholipid profiles that may be useful for the deep phenotyping of this disease. Design. Multiple reaction monitoring-mass spectrometry (MRM/MS) was applied to explore the potential phospholipidomic differences in the SF of knee OA patients (n ​= ​15) (subclassified into early- and late-stage OA) and non-OA controls (n ​= ​4). Multivariate statistical analyses conducted by partial least squares discriminant analysis (PLS-DA) and hierarchical clustering analysis (HCA) were performed to identify significantly altered phospholipids in OA, characterize phospholipidomic profiles associated with the radiographic stage of the disease and describe potential endotypes at early stages. Results. Significant discrimination of phospholipid profiles between non-OA controls and the early- and late-stage OA groups were found by PLS-DA and HCA. Compared to SF from non-OA controls, OA patients showed higher levels of most quantified phospholipid species, including phosphatidylcholines (PC), phosphatidylserines and phosphatidylinositols. Furthermore, several PC species showed significant differences in abundance between the two OA subgroups and were negatively correlated with cartilage damage. Finally, two distinct endotypes of early-stage OA were identified based on the phospholipidomic profile of SF. Conclusions. Our data provides a novel insight into the phospholipid profiles of OA synovial fluid, revealing specific alterations associated with the radiographic stage of the disease. This targeted phospholipidomic profiling also facilitated the characterization of two different OA endotypes at early stages of the disease., This work is supported by grants from Fondo Investigación Sanitaria-Spain (PI16/02124, PI17/00404, PI19/01206, PI20/00793 and RETIC-RIER-RD16/0012/0002), integrated in the National Plan for Scientific Program, Development and Technological Innovation 2013–2016 and funded by the ISCIII-General Subdirection of Assessment and Promotion of Research - European Regional Development Fund (FEDER) “A way of making Europe”. This study is also supported by AE CICA-INIBIC (ED431E 2018/03) and grants IN607A 2017/11, IN607A 2021/7 and IN607D 2020/10 from Axencia Galega de Innovacion - Xunta de Galicia. The Biomedical Research Networking Center (CIBER) is an initiative from Instituto de Salud Carlos III (ISCIII). The Proteomics Unit of GIR belongs to ProteoRed, PRB3- ISCIII (PT17/0019/0014), Xunta de Galicia; ED431E 2018/03, Xunta de Galicia; IN607A 2017/11, Xunta de Galicia; IN607A 2021/7, Xunta de Galicia; IN607D 2020/10
RUC. Repositorio da Universidade da Coruña
Publication Artículo científico (JournalArticle)

Identification of a distinct lipidomic profile in the osteoarthritic synovial membrane by mass spectrometry imaging

  • Rocha Loureda, Beatriz
  • Cillero-Pastor, B.
  • Ruiz-Romero, Cristina
  • Paine, Martin R.L.
  • Cañete, Juan D.
  • Heeren, Ron M.A.
  • Blanco García, Francisco J
[Abstract] Objective: Synovial inflammation is one of the most characteristic events in different types of arthritis, including Osteoarthritis (OA). Emerging evidence also suggests the involvement of lipids in the regulation of inflammatory processes. The aim of this study was to elucidate the heterogeneity and spatial distribution of lipids in the OA synovial membrane and explore their putative involvement in inflammation. Method: The abundance and distribution of lipids were examined in human synovial membranes. To this end, histological cuts from this tissue were analysed by matrix-assisted laser desorption ionization - mass spectrometry imaging (MALDI-MSI). The lipidomic profile of OA synovium was characterized and compared with healthy and other forms of inflammatory arthropathies as Rheumatoid Arthritis (RA) and Psoriatic Arthritis (PsA) using principal component analysis and discriminant analysis methods. Lipid identification was undertaken by tandem MS analyses and database queries. Results: Our results reveal differential and characteristic lipidomic profiles between OA and control samples. Specifically, we unveiled that OA synovium presents elevated levels of phosphatidylcholines, fatty acids and lysophosphatidic acids and lower levels of lysophosphatidylcholines compared to control tissues. The spatial distribution of particular glycerophospholipids was also correlated with hypertrophic, inflamed or vascularized synovial areas. Compared with other inflammatory arthritis, the OA tissue showed lower amounts of phosphatidylethanolamine-based plasmalogens. Conclusions: This study provides a novel insight into the lipid profiles of synovial membrane and differences in abundance between OA and control tissues. The lipidomic alterations improves understanding of the pathogenic mechanisms of OA and may be important for its diagnosis., This work is supported by grants from Fondo Investigación Sanitaria-Spain (PI16/02124, PI17/00404 PI19/01206 and RETIC-RIER-RD16/0012/0002), integrated in the National Plan for Scientific Program, Development and Technological Innovation 2013–2016 and funded by the ISCIII-General Subdirection of Assessment and Promotion of Research – European Regional Development Fund (FEDER) “A way of making Europe”. This study is also supported by AE CICA-INIBIC (ED431E 2018/03) and grants IN607A2017/11 and IN607D2020/10 from Xunta de Galicia. The Biomedical Research Networking Center (CIBER) is an initiative from Instituto de Salud Carlos III (ISCIII). The Proteomics Unit of GIR belongs to ProteoRed, PRB3- ISCIII (PT17/0019/0014). B.R. has been supported by Xunta de Galicia (IN606B-2016/004). The research was partially performed within the M4I research program, financially supported by the Dutch Province of Limburg as part of the “LINK” program, Xunta de Galicia; ED431E 2018/03, Xunta de Galicia; IN607A2017/11, Xunta de Galicia; IN607D2020/10, Xunta de Galicia; IN606B-2016/004
RUC. Repositorio da Universidade da Coruña
Publication Artículo científico (JournalArticle)

Mitochondrial DNA impact on joint damaged process in a conplastic mouse model after being surgically induced with osteoarthritis

  • Scotece, Morena
  • Rego-Pérez, I.
  • Lechuga-Vieco, Ana Victoria
  • Centeno, Alberto
  • Jiménez-Gómez, María Concepción
  • Filgueira-Fernández, P.
  • Vaamonde-García, Carlos
  • Enríquez, José Antonio
  • Blanco García, Francisco J
[Abstract] It has been suggested that mitochondrial dysfunction and mtDNA variations may contribute to osteoarthritis (OA) pathogenesis. However, the causative link to support this claim is lacking. Here, we surgically-induced OA in conplastic mice in order to evaluate the functional consequences of mtDNA haplotypes in their joint degeneration. BL/6NZB strain was developed with C57BL/6JOlaHsd nuclear genome and NZB/OlaHsdmtDNA while BL/6C57, which is the original, was developed with C57BL/6JOlaHsd nuclear genome and C57/OlaHsdmtDNA for comparison. The surgical DMM OA model was induced in both strains. Their knees were processed and examined for histopathological changes. Cartilage expression of markers of autophagy, apoptosis, oxidative stress and senescence were also analyzed by immunohistochemistry. The joints of BL/6NZB mice that were operated presented more cellularity together with a reduced OARSI histopathology score, subchondral bone, menisci score and synovitis compared to those of BL/6C57 mice. This was accompanied with higher autophagy and a lower apoptosis in the cartilage of BL/6NZB mice that were operated. Therefore, the study demonstrates the functional impact of non-pathological variants of mtDNA on OA process using a surgically-induced OA model. Conplastic (BL/6NZB ) mice develop less severe OA compared to the BL/6C57original strain. These findings demonstrate that mitochondria and mtDNA are critical targets for potential novel therapeutic approaches to treat osteoarthritis., This work is supported by grants from Fondo de Investigación Sanitaria (CIBERCB06/01/0040-Spain, RETIC-RIER-RD16/0012/0002, PI16/02124, PI19/01206) integrated in the National Plan for Scientific Program, Development and Technological Innovation 2013–2016 and funded by the ISCIII-General Sub direction of Assessment and Promotion of Research-European Regional Development Fund (FEDER)“A way of making Europe”. MS is “Sara Borrell” researcher funded by ISCIII and FEDER (CD16/00099). IRP is funded by the Instituto de Salud Carlos III through a Miguel Servet-II programme (CPII17/00026). CVG is supported by Contrato Posdoctoral Xunta de Galicia (ED481D2017/023).
RUC. Repositorio da Universidade da Coruña
Publication Artículo científico (JournalArticle)

mtDNA haplogroup A enhances the effect of obesity on the risk of knee OA in a mexican population

  • Ramos-Louro, Paula
  • Arellano Pérez Vertti, Rubén Daniel
  • López-Reyes, Alberto
  • Martínez-Nava, Gabriela Angélica
  • Espinosa, Rolando
  • Pineda, Carlos
  • González Galarza, Faviel Francisco
  • Argüello Astorga, Rafael
  • Aguilar Muñiz, Lizette Sarai
  • Hernández Terán, Fernando
  • Parra Torres, Nancy Marbella
  • Durán-Sotuela, Alejandro
  • Fernández-Moreno, Mercedes
  • Balboa-Barreiro, Vanesa
  • Blanco García, Francisco J
  • Rego-Pérez, I.
[Abstract] To evaluate the influence of mitochondrial DNA haplogroups on the risk of knee OA in terms of their interaction with obesity, in a population from Mexico. Samples were obtained from (n = 353) knee OA patients (KL grade ≥ I) and (n = 364) healthy controls (KL grade = 0) from Mexico city and Torreon (Mexico). Both Caucasian and Amerindian mtDNA haplogroups were assigned by single base extension assay. A set of clinical and demographic variables, including obesity status, were considered to perform appropriate statistical approaches, including chi-square contingency tables, regression models and interaction analyses. To ensure the robustness of the predictive model, a statistical cross-validation strategy of B = 1000 iterations was used. All the analyses were performed using boot, GmAMisc and epiR package from R software v4.0.2 and SPSS software v24. The frequency distribution of the mtDNA haplogroups between OA patients and healthy controls for obese and non-obese groups showed the haplogroup A as significantly over-represented in knee OA patients within the obese group (OR 2.23; 95% CI 1.22-4.05; p-value = 0.008). The subsequent logistic regression analysis, including as covariate the interaction between obesity and mtDNA haplogroup A, supported the significant association of this interaction (OR 2.57; 95% CI 1.24-5.32; p-value = 0.011). The statistical cross-validation strategy confirmed the robustness of the regression model. The data presented here indicate a link between obesity in knee OA patients and mtDNA haplogroup A., This work is supported by Grants from Fondo de Investigación Sanitaria (PI17/00210, PI16/02124, PI20/00614, RETIC-RIER-RD16/0012/0002 and PRB3-ISCIII-PT17/0019/0014) integrated in the National Plan for Scientific Program, Development and Technological Innovation 2013–2016 and funded by the ISCIII-General Subdirection of Assessment and Promotion of Research-European Regional Development Fund (FEDER) “A way of making Europe” and Grant IN607A2017/11 from Xunta de Galicia. The authors further acknowledge AE CICA-INIBIC (ED431E 2018/03) for financial support. IRP is supported by Contrato Miguel Servet-II Fondo de Investigación Sanitaria (CPII17/00026) and AD-S is supported by Grant IN606A-2018/023 from Xunta de Galicia, Spain. The Biomedical Research Networking Center (CIBER) is an initiative from Instituto de Salud Carlos III (ISCIII), Xunta de Galicia; IN607A2017/11, Xunta de Galicia; ED431E 2018/03, Xunta de Galicia; IN606A-2018/023
RUC. Repositorio da Universidade da Coruña
Publication Artículo científico (JournalArticle)

A clinical model including protein biomarkers predicts radiographic knee osteoarthritis: a prospective study using data from the Osteoarthritis Initiative

  • Lourido Salas, Lucía María
  • Balboa-Barreiro, Vanesa
  • Ruiz-Romero, Cristina
  • Rego-Pérez, I.
  • Camacho Encina, María
  • Paz González, Rocío
  • Calamia, Valentina
  • Oreiro Villar, Natividad
  • Nilsson, Peter
  • Blanco García, Francisco J
The Osteoarthritis Initiative (OAI) is a public-private partnership comprised of five contracts (N01-AR-2-2258; N01-AR-2-2259; N01-AR-2-2260; N01-AR-2-2261; N01-AR-2-2262) funded by the National Institutes of Health, a branch of the Department of Health and Human Services, and conducted by the OAI Study Investigators. Private funding partners include Pfizer, Inc.; Novartis Pharmaceuticals Corporation; Merck Research Laboratories; and GlaxoSmithKline. Private sector funding for the OAI is managed by the Foundation for the National Institutes of Health. This work has been supported by grants from Fondo Investigación Sanitaria (PI16/02124, PI17/00404, PI19/01206, DTS17/00200, CIBER-CB06/01/0040 and RETIC-RIER-RD16/0012/0002), integrated in the National Plan for Scientific Program, Development and Technological Innovation 2013–2016 and funded by the ISCIII-General Subdirection of Assessment and Promotion of Research-European Regional Development Fund (FEDER) “A way of making Europe”. This study has been also supported by grants IN607A2017/11, IN607D2020/10 and AE CICA-INIBIC (ED431E 2018/03) from Xunta de Galicia. The Proteomics Unit of GIR belongs to ProteoRed, PRB3- ISCIII (PT17/0019/0014). L.L. is supported by Xunta de Galicia (IN606B-2016/2005) and Contrato Sara Borrell (CD19/00229) Fondo de Investigación Sanitaria, ISCIII. I.R.P. is supported by Contrato Miguel Servet-II Fondo de Investigación Sanitaria (CPII17/00026). This work was also supported by the KTH Center for Applied Precision Medicine funded by the Ehrling Persson foundation, as well as the Human Protein Atlas project funded by Knut and Alice Wallenberg Foundation, Xunta de Galicia; IN607A2017/11, Xunta de Galicia; IN607D2020/10, Xunta de Galicia; ED431E 2018/03, Xunta de Galicia; IN606B-2016/2005
RUC. Repositorio da Universidade da Coruña
Publication Artículo científico (JournalArticle)

Proteomic analysis of synovial fibroblasts and articular chondrocytes co-cultures reveals valuable VIP-modulated inflammatory and degradative proteins in osteoarthritis

  • Pérez-García, Selene
  • Calamia, Valentina
  • Hermida Gómez, Tamara
  • Gutiérrez-Cañas, Irene
  • Carrión, Mar
  • Villanueva-Romero, Raúl
  • Castro Vázquez, David
  • Martínez, Carmen
  • Juarranz, Yasmina
  • Blanco García, Francisco J
  • Gomariz, Rosa P.
[Abstract] Osteoarthritis (OA) is the most common musculoskeletal disorder causing a great disability and a reduction in the quality of life. In OA, articular chondrocytes (AC) and synovial fibroblasts (SF) release innate-derived immune mediators that initiate and perpetuate inflammation, inducing cartilage extracellular matrix (ECM) degradation. Given the lack of therapies for the treatment of OA, in this study, we explore biomarkers that enable the development of new therapeutical approaches. We analyze the set of secreted proteins in AC and SF co-cultures by stable isotope labeling with amino acids (SILAC). We describe, for the first time, 115 proteins detected in SF-AC co-cultures stimulated by fibronectin fragments (Fn-fs). We also study the role of the vasoactive intestinal peptide (VIP) in this secretome, providing new proteins involved in the main events of OA, confirmed by ELISA and multiplex analyses. VIP decreases proteins involved in the inflammatory process (CHI3L1, PTX3), complement activation (C1r, C3), and cartilage ECM degradation (DCN, CTSB and MMP2), key events in the initiation and progression of OA. Our results support the anti-inflammatory and anti-catabolic properties of VIP in rheumatic diseases and provide potential new targets for OA treatment., This research was funded by the Fondo de Investigación Sanitaria, Instituto de Salud Carlos III, grant numbers PI17/00027, PI20/00078, RD16/0012/0008 and RD16/0012/0002, co-financed by Fondo Europeo de Desarrollo Regional (FEDER)
RUC. Repositorio da Universidade da Coruña
Publication Artículo científico (JournalArticle)

The Treatment With the SGLT2 Inhibitor Empagliflozin Modifies the Hepatic Metabolome of Male Zucker Diabetic Fatty Rats Towards a Protective Profile

  • Aragón Herrera, Alana
  • Otero-Santiago, Manuel
  • Anido Varela, Laura
  • Moraña Fernández, Sandra
  • Campos-Toimil, Manuel
  • García-Caballero, Tomás
  • Barral, Luis
  • Tarazón, Estefanía
  • Roselló-Lletí, Esther
  • Portolés, Manuel
  • Gualillo, Oreste
  • Moscoso, Isabel
  • Lage Fernández, Ricardo
  • González-Juanatey, José Ramón
  • Feijóo-Bandín, Sandra
  • Lago, Francisca
[Abstract] The EMPA-REG OUTCOME (Empagliflozin, Cardiovascular Outcome Event Trial in patients with Type 2 Diabetes Mellitus (T2DM)) trial evidenced the potential of sodium-glucose cotransporter 2 (SGLT2) inhibitors for the treatment of patients with diabetes and cardiovascular disease. Recent evidences have shown the benefits of the SGLT2 inhibitor empagliflozin on improving liver steatosis and fibrosis in patients with T2DM. Metabolomic studies have been shown to be very useful to improve the understanding of liver pathophysiology during the development and progression of metabolic hepatic diseases, and because the effects of empagliflozin and of other SGLT2 inhibitors on the complete metabolic profile of the liver has never been analysed before, we decided to study the impact on the liver of male Zucker diabetic fatty (ZDF) rats of a treatment for 6 weeks with empagliflozin using an untargeted metabolomics approach, with the purpose to help to clarify the benefits of the use of empagliflozin at hepatic level. We found that empagliflozin is able to change the hepatic lipidome towards a protective profile, through an increase of monounsaturated and polyunsaturated glycerides, phosphatidylcholines, phosphatidylethanolamines, lysophosphatidylinositols and lysophosphatidylcholines. Empagliflozin also induces a decrease in the levels of the markers of inflammation IL-6, chemerin and chemerin receptor in the liver. Our results provide new evidences regarding the molecular pathways through which empagliflozin could exert hepatoprotector beneficial effects in T2DM., This work was supported by Boehringer Ingelheim Pharma GmbH and Co., by the National Institute of Health “Fondo de Investigaciones Sanitarias del Instituto de Salud Carlos III” Madrid, Spain (PI15/00681, PI17/00409, PI18/00821, PI20/00902, RETICS Programme RD16/0012/0014 and CIBER de Enfermedades Cardiovasculares (CIBERCV)); European Regional Development Fund (FEDER) and European Union framework MSCA-RISE-H2020 Programme (Project number 734899). AH-A was funded by predoctoral research grants from Xunta de Galicia and FPU Program of the Spanish Ministry of Science, Innovation and Universities (Spain); MF-S was funded by the predoctoral research grants “Programa Científico do Centro de Investigación en Medicina Molecular e Enfermidades Crónicas (CiMUS) (Spain) and Xunta de Galicia; and AV-L was funded by the predoctoral research grant from the PFIS Program of the Spanish Ministry of Science and Instituto de Salud Carlos III (Spain)
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

IgA Vasculitis: Influence of CD40, BLK and BANK1 Gene Polymorphisms

  • Batista-Liz, Joao Carlos
  • Genre, Fernanda
  • Pulito-Cueto, Verónica
  • Remuzgo-Martínez, Sara
  • Prieto-Peña, Diana
  • Márquez, Ana
  • Ortego-Centeno, Norberto
  • Leonardo, María Teresa
  • Peñalba, Ana
  • Narváez, Javier
  • Martín-Penagos, Luis
  • Belmar-Vega, Lara
  • Gómez Fernández, Cristina
  • Miranda-Filloy, J. A.
  • Caminal-Montero, Luis
  • Collado, Paz
  • Árgila, Diego de
  • Quiroga, Patricia
  • Vicente, Esther
  • Triguero-Martínez, Ana
  • Rubio, Esteban
  • León Luque, Manuel
  • Blanco-Madrigal, Juan María
  • Galíndez-Agirregoikoa, E.
  • Martín, Javier
  • Gualillo, Oreste
  • Blanco, Ricardo
  • Castañeda, Santos
  • González-Gay, Miguel A.
  • López-Mejías, Raquel
CD40, BLK and BANK1 genes involved in the development and signaling of B-cells are identified as susceptibility loci for numerous inflammatory diseases. Accordingly, we assessed the potential influence of CD40, BLK and BANK1 on the pathogenesis of immunoglobulin-A vasculitis (IgAV), predominantly a B-lymphocyte inflammatory condition. Three genetic variants within CD40 (rs1883832, rs1535045, rs4813003) and BLK (rs2254546, rs2736340, rs2618476) as well as two BANK1 polymorphisms (rs10516487, rs3733197), previously associated with inflammatory diseases, were genotyped in 382 Caucasian patients with IgAV and 955 sex- and ethnically matched healthy controls. No statistically significant differences were observed in the genotype and allele frequencies of CD40, BLK and BANK1 when IgAV patients and healthy controls were compared. Similar results were found when CD40, BLK and BANK1 genotypes or alleles frequencies were compared between patients with IgAV stratified according to the age at disease onset or to the presence/absence of gastrointestinal or renal manifestations. Moreover, no CD40, BLK and BANK1 haplotype differences were disclosed between patients with IgAV and healthy controls and between patients with IgAV stratified according to the clinical characteristics mentioned above. Our findings indicate that CD40, BLK and BANK1 do not contribute to the genetic background of IgAV., This study was supported by European Union FEDER funds and “Fondo de Investigaciones Sanitarias” (grants PI18/00042 and PI21/00042) from “Instituto de Salud Carlos III” (ISCIII, Health Ministry, Spain). D.P.-P. is a recipient of a Río Hortega program fellowship from the ISCIII, co-funded by the European Social Fund (ESF, “Investing in your future”) (grant number CM20/00006). F.G. is supported by funds of the RICORS Program from ISCIII, co-funded by the European Union (grant number RD21/0002/0025). V.P.-C. is supported by funds of PI18/00042. S.R.-M. is supported by funds of the RETICS Program (RD16/0012/0009) (ISCIII, co-funded by the European Regional Development Fund (ERDF)). O.G. is a staff member of Xunta de Galicia (Servizo Galego de Saude (SERGAS)) through a research-staff stabilization contract (ISCIII/SERGAS) and his work is funded by ISCIII and the European Union FEDER fund (grant numbers RD16/0012/0014 (RIER) and PI17/00409). He is a beneficiary of project funds from the Research Executive Agency (REA) of the European Union in the framework of MSCA-RISE Action of the H2020 Program, project 734899—Olive-Net. R.L.-M. is a recipient of a Miguel Servet type II program fellowship from the ISCIII, co-funded by ESF (“Investing in your future”) (grant number CPII21/00004)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

A summary on the genetics of Systemic Lupus erythematosus, rheumatoid arthritis, systemic sclerosis, and Sjögren’s syndrome

  • Ortiz-Fernández, Lourdes
  • Martín, Javier
  • Alarcón-Riquelme, M. E.
Systemic lupus erythematosus, systemic sclerosis, rheumatoid arthritis, and Sjögren’s syndrome are four major autoimmune rheumatic diseases characterized by the presence of autoantibodies, caused by a dysregulation of the immune system that leads to a wide variety of clinical manifestations. These conditions present complex etiologies strongly influenced by multiple environmental and genetic factors. The human leukocyte antigen (HLA) region was the first locus identified to be associated and still represents the strongest susceptibility factor for each of these conditions, particularly the HLA class II genes, including DQA1, DQB1, and DRB1, but class I genes have also been associated. Over the last two decades, the genetic component of these disorders has been extensively investigated and hundreds of non-HLA risk genetic variants have been uncovered. Furthermore, it is widely accepted that autoimmune rheumatic diseases share molecular disease pathways, such as the interferon (IFN) type I pathways, which are reflected in a common genetic background. Some examples of well-known pleiotropic loci for autoimmune rheumatic diseases are the HLA region, DNASEL13, TNIP1, and IRF5, among others. The identification of the causal molecular mechanisms behind the genetic associations is still a challenge. However, recent advances have been achieved through mouse models and functional studies of the loci. Here, we provide an updated overview of the genetic architecture underlying these four autoimmune rheumatic diseases, with a special focus on the HLA region., This work was supported by the Spanish Ministry of Science and Innovation RTI2018-101332-B-100 to JM and PID2020-113776 Gb-I00 to MEAR), Red de Investigación en Inflamación y Enfermedades Reumáticas (RIER) from Instituto de Salud Carlos III (RD16/0012/0013 to JM), the Consejería de Salud y Familias (PE-0297–2019 to MEAR), and the Consejería de Transformación económica, industria, conocimiento y universidades (PY20-00473 to MEAR). LOF was funded by the Spanish Ministry of Science and Innovation through the Juan de la Cierva Incorporacion program (ref. IJC2019-040746-I)
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

GWAS for systemic sclerosis identifies multiple risk loci and highlights fibrotic and vasculopathy pathways

  • López-Isac, E.
  • Acosta-Herrera, M.
  • Kerick, M.
  • Assassi, S.
  • Satpathy, A.T.
  • Granja, J.
  • Mumbach, M.R.
  • Beretta, L.
  • Simeón, C.P.
  • Carreira, P.
  • Ortego-Centeno, N.
  • Castellvi, I.
  • Bossini-Castillo, L.
  • Carmona, F.D.
  • Orozco, G.
  • Hunzelmann, N.
  • Distler, J.H.W.
  • Franke, A.
  • Lunardi, C.
  • Moroncini, G.
  • Gabrielli, A.
  • de Vries-Bouwstra, J.
  • Wijmenga, C.
  • Koeleman, B.P.C.
  • Nordin, A.
  • Padyukov, L.
  • Hoffmann-Vold, A.-M.
  • Lie, B.
  • Ríos, R.
  • Callejas, J.L.
  • Vargas-Hitos, J.A.
  • García-Portales, R.
  • Camps, M.T.
  • Fernández-Nebro, A.
  • González-Escribano, M.F.
  • García-Hernández, F.J.
  • Castillo, M.J.
  • Aguirre, M.A.
  • Gómez-Gracia, I.
  • Fernández-Gutiérrez, B.
  • Rodríguez-Rodríguez, L.
  • García de la Peña, P.
  • Vicente, E.
  • Andreu, J.L.
  • Fernández de Castro, M.
  • López-Longo, F.J.
  • Martínez, L.
  • Fonollosa, V.
  • Guillén, A.
  • Espinosa, G.
  • Tolosa, C.
  • Pros, A.
  • Rodríguez-Carballeira, M.
  • Narváez, F.J.
  • Rubio-Rivas, M.
  • Ortiz-Santamaría, V
  • Madroñero, A.B.
  • González-Gay, M.A.
  • Díaz, B.
  • Trapiella, L.
  • Sousa, A.
  • Egurbide, M.V.
  • Fanlo-Mateo, P.
  • Sáez-Comet, L.
  • Díaz, F.
  • Hernández, V
  • Beltrán, E.
  • Román-Ivorra, J.A.
  • Grau E.
  • Alegre-Sancho, J.J.
  • Freire, M.
  • Blanco-García, F.J.
  • Oreiro, N.
  • Witte, T.
  • Kreuter, A.
  • Riemekasten, G.
  • Airó P.
  • Magro, C.
  • Voskuyl, A.E.
  • Vonk, M.C.
  • Hesselstrand, R.
  • Proudman S.
  • Stevens, W.
  • Nikpour, M.
  • Zochling, J.
  • Sahhar, J.
  • Roddy, J.
  • Nash, P.
  • Tymms, K.
  • Rischmueller, M.
  • Lester, S.
  • Vyse, T.
  • Herrick, A.L.
  • Worthington, J.
  • Denton C.P.
  • Allanore, Y.
  • Brown, M.A.
  • Radstake, T.R.D.J.
  • Fonseca, C.
  • Chang H.Y.
  • Mayes, M.D.
  • Martin, J.
  • European Scleroderma Group
  • Australian Scleroderma Interest Group (ASIG)
Systemic sclerosis (SSc) is an autoimmune disease that shows one of the highest mortality rates among rheumatic diseases. We perform a large genome-wide association study (GWAS), and meta-analysis with previous GWASs, in 26, 679 individuals and identify 27 independent genome-wide associated signals, including 13 new risk loci. The novel associations nearly double the number of genome-wide hits reported for SSc thus far. We define 95% credible sets of less than 5 likely causal variants in 12 loci. Additionally, we identify specific SSc subtype-associated signals. Functional analysis of high-priority variants shows the potential function of SSc signals, with the identification of 43 robust target genes through HiChIP. Our results point towards molecular pathways potentially involved in vasculopathy and fibrosis, two main hallmarks in SSc, and highlight the spectrum of critical cell types for the disease. This work supports a better understanding of the genetic basis of SSc and provides directions for future functional experiments.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

A cross-disease meta-GWAS identifies four new susceptibility loci shared between systemic sclerosis and Crohn’s disease

  • González-Serna, D.
  • Ochoa, E.
  • López-Isac, E.
  • Julià, A.
  • Degenhardt, F.
  • Ortego-Centeno, N.
  • Radstake, T.R.D.J.
  • Franke, A.
  • Marsal, S.
  • Mayes, M.D.
  • Martín, J.
  • Márquez, A.
  • Assassi, S.
  • Zhou, X.
  • Tan, F.K.
  • Arnett, F.C.
  • Reveille, J.D.
  • Gorlova, O.
  • Chen, W.V.
  • Ying, J.
  • Gregersen, P.K.
  • Lee, A.T.
  • Voskuyl, A.E.
  • de Vries-Bouwstra, J.
  • Magro-Checa, C.
  • Broen, J.
  • Koeleman, B.P.C.
  • Simeón, C.P.
  • Fonollosa, V.
  • Guillén, A.
  • Carreira, P.
  • Castellví, I.
  • González-Gay, M.A.
  • Ríos, R.
  • Callejas-Rubio, J.L.
  • Vargas-Hitos, J.A.
  • García-Portales, R.
  • Camps, M.T.
  • Fernández-Nebro, A.
  • González-Escribano, M.F.
  • García-Hernández, F.J.
  • Castillo, M.J.
  • Aguirre, M.Á.
  • Gómez-Gracia, I.
  • Rodríguez-Rodríguez, L.
  • Fernández-Gutiérrez, B.
  • de la Peña, P.G.
  • Vicente, E.
  • Andreu, J.L.
  • Fernández de Castro, M.
  • López-Longo, F.J.
  • Martínez, L.
  • Espinosa, G.
  • Tolosa, C.
  • Pros, A.
  • Rodríguez-Carballeira, M.
  • Narváez, F.J.
  • Rubio-Rivas, M.
  • Ortiz-Santamaría, V.
  • Madroñero, A.B.
  • Díaz, B.
  • Trapiella, L.
  • Sousa, A.
  • Egurbide, M.V.
  • Fanlo-Mateo, P.
  • Sáez-Comet, L.
  • Díaz-González, F.
  • Hernández, V.
  • Beltrán, E.
  • Román-Ivorra, J.A.
  • Grau, E.
  • Alegre-Sancho, J.J.
  • Blanco-García, F.J.
  • Oreiro, N.
  • Freire, M.
  • Balsa, A.
  • Ortiz, A.M.
  • Hunzelmann, N.
  • Riemekasten, G.
  • Distler, J.H.W.
  • Witte, T.
  • Airó, P.
  • Beretta, L.
  • Santaniello, A.
  • Bellocchi, C.
  • Lunardi, C.
  • Moroncini, G.
  • Gabrielli, A.
  • Scleroderma, Genetic, Consortium
Genome-wide association studies (GWASs) have identified a number of genetic risk loci associated with systemic sclerosis (SSc) and Crohn’s disease (CD), some of which confer susceptibility to both diseases. In order to identify new risk loci shared between these two immune-mediated disorders, we performed a cross-disease meta-analysis including GWAS data from 5, 734 SSc patients, 4, 588 CD patients and 14, 568 controls of European origin. We identified 4 new loci shared between SSc and CD, IL12RB2, IRF1/SLC22A5, STAT3 and an intergenic locus at 6p21.31. Pleiotropic variants within these loci showed opposite allelic effects in the two analysed diseases and all of them showed a significant effect on gene expression. In addition, an enrichment in the IL-12 family and type I interferon signaling pathways was observed among the set of SSc-CD common genetic risk loci. In conclusion, through the first cross-disease meta-analysis of SSc and CD, we identified genetic variants with pleiotropic effects on two clinically distinct immune-mediated disorders. The fact that all these pleiotropic SNPs have opposite allelic effects in SSc and CD reveals the complexity of the molecular mechanisms by which polymorphisms affect diseases.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

The comparative responsiveness of Hospital Universitario Princesa Index and other composite indices for assessing rheumatoid arthritis activity

  • Gonzalez-Alvaro, I.
  • Castrejon, I.
  • Carmona, L.
  • Dougados, M.
  • Huizinga, T.
  • Abu Shakra, M.
  • Alberts, A.
  • Lopez, M.A.
  • Amital, H.
  • Aringer, M.
  • Aslanidis, S.
  • Berenbaum, F.
  • Bijlsma, H.
  • Garcia, F.J.B.
  • Bliddal, H.
  • Borofsky, M.
  • Brocq, O.
  • Buldakov, S.
  • Cantini, F.
  • Perez, L.C.
  • Chahade, W.
  • Ciconelli, R.
  • Codreanu, C.
  • Dahlqvist, S.R.
  • Damjanov, N.
  • Diamantopoulos, A.
  • Dimdina, L.
  • Dimic, A.
  • Dorokhov, A.
  • Dubikov, A.
  • Fadienko, G.
  • Fano, N.
  • Ferreira, G.
  • Gabrielli, A.
  • Gaffney, K.
  • Gaudin, P.
  • Gerlag, D.M.
  • Gerli, R.
  • Goncalves, C.R.
  • Hansen, M.S.
  • Hanvivadhanakul, P.
  • Hoili, C.
  • Hou, A.
  • Hunter, J.
  • Ilic, T.
  • Ionescu, R.
  • Kaine, J.
  • Kakurina, N.
  • Kamalova, R.
  • Kelly, T.
  • Knyazeva, L.
  • Krumina, L.
  • Kurthen, R.
  • Lagrone, R.P.
  • Lapadula, G.
  • Lavrentjevs, V.
  • Lawson, J.G.
  • Lazic, Z.
  • Lejnieks, A.
  • Levy, Y.
  • Lexberg, A.
  • Mader, R.
  • Mariette, X.
  • Markovits, D.
  • Mola, E.M.
  • Maugars, Y.
  • Guarch, J.M.
  • Mazurov, V.I.
  • Mikkelsen, K.
  • Vergles, J.M.
  • Nabizadeh, S.
  • Nanagara, R.
  • Nasonov, E.L.
  • Sarabia, F.N.
  • Neumann, T.
  • Novak, S.
  • Olech, E.
  • Oza, M.
  • Paran, D.
  • Parsik, E.
  • Pegram, S.
  • Suarez, M.P.
  • Popova, T.
  • Puechal, X.
  • Raja, N.
  • Ridley, D.
  • Rosner, I.
  • Rubbert-Roth, A.
  • Rudin, A.
  • Saraux, A.
  • Saulite-Kandevica, D.
  • Settas, L.
  • Sfikakis, P.
  • Sheeran, T.
  • Sizikov, A.
  • Stamenkovic, D.
  • Stefanovic, D.
  • Stolow, J.B.
  • Tan, A.L.
  • Tebib, J.
  • Tishler, M.
  • Tony, H.P.
  • Troum, O.M.
  • Uaratanawong, S.
  • Angulo, E.U.
  • Valenzuela, G.
  • van der Laken, K.
  • Van Laar, J.
  • van Riel, P.L.C.M.
  • Vasilopoulos, D.
  • Veldi, T.
  • Vinogradova, I.
  • Vosse, D.
  • Wassenberg, S.
  • Weidmann, C.
  • Weitz, M.
  • Wollenhaupt, J.
  • Xavier, R.
  • Yakupova, S.
  • Zagar, I.
  • Zavgorodnaja, T.
  • Zemerova, E.
  • Zisman, D.
  • Zonova, E.
  • Camona, L.
  • Alcazar, L.A.
  • de Miguel, C.A.
  • Sanchez, J.L.A.
  • Diez, A.A.
  • Criado, A.B.
  • Gualda, E.B.
  • Serrano, M.A.B.
  • Audera, J.B.
  • Fabregat, J.B.
  • Hernan, G.B.
  • Fernandez, N.C.
  • Casado, E.
  • Mendez, L.C.
  • Coro, M.C.
  • Diaz, J.L.C.
  • Cuesta, E.
  • Areste, J.F.
  • Gonzalez, M.F.
  • Izquierdo, M.G.
  • Meijide, J.A.G.
  • Gomez, M.C.G.
  • Ubeda, E.G.
  • Centeno, E.G.
  • Vaquero, C.G.
  • Fernandez, M.J.G.
  • Gomez, M.L.G.
  • Hernandez, T.G.
  • Gonzalez-Alvaro, I.
  • Gomez, C.G.M.
  • Delgado, Y.G.
  • Masmitja, J.G.
  • del Rio, A.H.
  • Instxaurbe, A.R.
  • Oyarzabal, M.V.I.
  • Palop, J.
  • Mas, A.J.
  • Navarro, E.J.
  • Padro, M.L.
  • Longo, F.J.L.
  • Santamaria, E.L.
  • Manzano, J.M.
  • Ruiz, F.J.M.
  • Bernardo, I.M.
  • Gonzalez, L.M.
  • Mazzucheli, R.
  • Medrano San Idelfonso, M.
  • Hernandez, A.N.
  • Espanol, A.P.
  • Callizo, E.P.
  • Donate, J.Q.
  • Lopez, P.R.
  • Redondo, J.R.
  • Gomez, M.R.
  • Lopez, M.R.
  • Pardo, R.R.
  • Alvarez, J.S.
  • Sala, R.S.
  • Rey, J.S.R.
  • Marsa, X.T.
  • Martin, M.T.
  • Martin, M.C.T.
  • Garnica, I.U.
  • de Diego, J.P.V.
  • Valls, M.
  • Garcia, V.V.
  • Montejo, P.Z.
  • Tabernero, J.Z.
  • Balsa, A.
  • Sanmarti, R.
  • Cabezas, J.A.
  • Cantalejo, M.
  • Chamizo, E.
  • Ciruelo, E.
  • Corrales, A.
  • Cruz, A.
  • Diaz, C.
  • Fiter, J.
  • Freire, M.M.
  • Galindo, M.
  • de Vicuna, M.R.G.
  • Gelman, S.M.
  • Crespo, R.G.
  • Fernandez, C.G.
  • Fernandez, M.J.G.
  • Hernandez, T.G.
  • Gracia, A.
  • Granados, J.
Objective To evaluate the responsiveness in terms of correlation of the Hospital Universitario La Princesa Index (HUPI) comparatively to the traditional composite indices used to assess disease activity in rheumatoid arthritis (RA), and to compare the performance of HUPI-based response criteria with that of the EULAR response criteria. Methods Secondary data analysis from the following studies: ACT-RAY (clinical trial), PROAR (early RA cohort) and EMECAR (pre-biologic era long term RA cohort). Responsiveness was evaluated by: 1) comparing change from baseline (Delta) of HUPI with Delta in other scores by calculating correlation coefficients; 2) calculating standardised effect sizes. The accuracy of response by HUPI and by EULAR criteria was analyzed using linear regressions in which the dependent variable was change in global assessment by physician (Delta GDA-Phy). Results Delta HUPI correlation with change in all other indices ranged from 0.387 to 0.791); HUPI's standardized effect size was larger than those from the other indices in each database used. In ACT-RAY, depending on visit, between 65 and 80% of patients were equally classified by HUPI and EULAR response criteria. However, HUPI criteria were slightly more stringent, with higher percentage of patients classified as non-responder, especially at early visits. HUPI response criteria showed a slightly higher accuracy than EULAR response criteria when using Delta GDA-Phy as gold standard. Conclusion HUPI shows good responsiveness in terms of correlation in each studied scenario (clinical trial, early RA cohort, and established RA cohort). Response criteria by HUPI seem more stringent than EULAR''s.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Role of VEGF Polymorphisms in the Susceptibility and Severity of Interstitial Lung Disease

  • Remuzgo-Martínez, Sara
  • Genre, Fernanda
  • Pulito-Cueto, Verónica
  • Atienza-Mateo, Belén
  • Mora Cuesta, Víctor Manuel
  • Iturbe Fernández, David
  • Berastegui Garcia, Cristina
Biomarker; Interstitial lung disease; Vascular endothelial growth factor, Biomarcador; Malaltia pulmonar intersticial; Factor de creixement endotelial vascular, Biomarcador; Enfermedad pulmonar intersticial; Factor de crecimiento vascular endotelial, The search for biomarkers that can help to establish an early diagnosis and prognosis of interstitial lung disease (ILD) is of potential interest. VEGF polymorphisms have been implicated in the development of several lung disorders. Consequently, we assessed, for the first time, the role of VEGF polymorphisms in the susceptibility and severity of ILD. A total of 436 Caucasian ILD patients (244 with idiopathic interstitial pneumonias (IIPs) and 192 with non-IIP) and 536 ethnically-matched healthy controls were genotyped for VEGF rs833061, rs1570360, rs2010963, rs3025020, and rs3025039 polymorphisms by TaqMan assays. Pulmonary function tests were collected from all the patients. VEGF serum levels were determined by ELISA in a subgroup of patients. No VEGF genotype, allele, carrier, or haplotype differences were found between ILD patients and controls as well as between IIP and non-IIP patients. However, an association of rs1570360 with IIP in women and also with lung function in IIP patients was found. None of the VEGF polymorphisms were associated with VEGF levels. In conclusion, our results suggest that VEGF does not seem to play a relevant role in ILD, although rs1570360 may influence the severity of ILD in women and a worse outcome in IIP patients., This research was partially supported by a grant from Spanish Society of Pulmonology and Thoracic Surgery (SEPAR 474-2017). S.R.-M. was supported by funds of the RETICS Program (RD16/0012/0009) from the “Instituto de Salud Carlos III” (ISCIII), co-funded by the European Regional Development Fund. V.P.-C. was supported by a pre-doctoral grant from IDIVAL (PREVAL 18/01). B.A.-M. was recipient of a “López Albo” post-residency program funded by Servicio Cántabro de Salud. L.L.-G. was supported by funds from IDIVAL (INNVAL 20/06). O.G. was beneficiary of a grant funded by Xunta de Galicia, Consellería de Educación, Universidade e Formación Profesional and Consellería de Economía, Emprego e Industria (GAIN), GPC IN607B2019/10. R.L.-M. was a recipient of a Miguel Servet type I program fellowship from the ISCIII, co-funded by the ESF, “Investing in your future” (grant CP16/00033).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Synovial Immunohistological Biomarkers of the Classification of Undifferentiated Arthritis Evolving to Rheumatoid or Psoriatic Arthritis

  • Cuervo, Andrea
  • Celis, Raquel
  • Julia Cano, Antonio
  • Usategui, Alicia
  • Faré, Regina
  • Ramírez, Julio
Artritis psoriàsica; Artritis reumatoide; Sinovitis, Artritis psoriásica; Artritis reumatoide; Sinovitis, Psoriatic arthritis; Rheumatoid arthritis; Synovitis, Background: Undifferentiated arthritis (UA) is defined as an inflammatory arthritis that does not fulfill criteria for a definite diagnosis. Delay in reaching a specific diagnostic and therapy may lead to impaired functional outcomes. Our aim was to identify synovial biomarkers associated with definitive diagnostic classification in patients with UA. Methods: DMARD-naïve UA patients with available initial synovial tissue (ST) and a final diagnosis of rheumatoid arthritis (RA) or psoriatic arthritis (PsA) during follow-up were included and compared with patients with well-defined disease (RA or PsA). Clinical, arthroscopic, and pathological data were compared between groups. Pathology included quantitative immunohistochemical (IHC) analysis of cell types and human interferon-regulated MxA. Principal component analysis (PCA) was performed to extract disease patterns. Results: One hundred and five patients were included: 31 patients with DMARD-naïve UA (19 evolving to RA and 12 to PsA during a median follow up of 7 years), 39 with established RA, and 35 with established PsA. ST from the UA group showed higher macrophage density compared with the established RA and PsA groups. Patients with UA evolving to RA (UA-RA) showed higher MxA expression and CD3+ T-cell density compared with established RA. UA patients evolving to PsA (UA-PsA) showed increased vascularity and lining synovial fibroblast density compared with established PsA. Synovitis of UA-PsA patients showed more mast cells and lining fibroblasts compared with UA-RA. No between-group differences in local or systemic inflammation markers were found. Conclusions: Our results show differences in the cellular composition of UA synovium compared with RA and PsA, with higher density of the cellular infiltrate in the UA groups. Initial expression of the interferon inducible gene MxA could be a biomarker of progression to RA, while higher mast cell and fibroblastic density may be associated with PsA progression., This research was supported by Instituto de Salud Carlos III (ISCIII) through the PI14/00785 and RD16/0012 RETICS program, cofinanced by the European Regional Development Fund (FEDER), “Una manera de hacer Europa”. AC also received grants from Sociedad Española de Reumatología (BECA FER-2015), Hospital Clinic de Barcelona, Projectes Fi de Residencia: Premis Emili Letang, and from Sociedad Catalana de Reumatología.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Epigenomics and transcriptomics of systemic sclerosis CD4+ T cells reveal long-range dysregulation of key inflammatory pathways mediated by disease-associated susceptibility loci

  • Li, Tianlu|||0000-0001-7152-4870
  • Ortiz-Fernández, Lourdes|||0000-0002-0247-4280
  • Andrés-León, Eduardo|||0000-0002-0621-9914
  • Ciudad, Laura|||0000-0002-5219-6792
  • Javierre, B. M.|||0000-0002-8682-6748
  • López-Isac, E.
  • Guillén-Del-Castillo, A.
  • Simeón-Aznar, C. P.
  • Ballestar, Esteban|||0000-0002-1400-2440
  • Martín, Javier|||0000-0002-2202-0622
Background: Systemic sclerosis (SSc) is a genetically complex autoimmune disease mediated by the interplay between genetic and epigenetic factors in a multitude of immune cells, with CD4+ T lymphocytes as one of the principle drivers of pathogenesis. Methods: DNA samples exacted from CD4+ T cells of 48 SSc patients and 16 healthy controls were hybridized on MethylationEPIC BeadChip array. In parallel, gene expression was interrogated by hybridizing total RNA on Clariom™ S array. Downstream bioinformatics analyses were performed to identify correlating differentially methylated CpG positions (DMPs) and differentially expressed genes (DEGs), which were then confirmed utilizing previously published promoter capture Hi-C (PCHi-C) data. Results: We identified 9112 and 3929 DMPs and DEGs, respectively. These DMPs and DEGs are enriched in functional categories related to inflammation and T cell biology. Furthermore, correlation analysis identified 17,500 possible DMP-DEG interaction pairs within a window of 5 Mb, and utilizing PCHi-C data, we observed that 212 CD4+ T cell-specific pairs of DMP-DEG also formed part of three-dimensional promoter-enhancer networks, potentially involving CTCF. Finally, combining PCHi-C data with SSc GWAS data, we identified four important SSc-associated susceptibility loci, TNIP1 (rs3792783), GSDMB (rs9303277), IL12RB1 (rs2305743), and CSK (rs1378942), that could potentially interact with DMP-DEG pairs cg17239269-ANXA6, cg19458020-CCR7, cg10808810-JUND, and cg11062629-ULK3, respectively. Conclusion: Our study unveils a potential link between genetic, epigenetic, and transcriptional deregulation in CD4+ T cells of SSc patients, providing a novel integrated view of molecular components driving SSc pathogenesis.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Body Mass Index and Disease Activity in Chronic Inflammatory Rheumatic Diseases, Results of the Cardiovascular in Rheumatology (Carma) Project

  • Valero-Jaimes, Jesús A.
  • López-González, Ruth
  • Martín-Martínez, María A.
  • García-Gómez, Carmen
  • Sánchez-Alonso, Fernando
  • Sánchez Costa, Jesús T.
  • González-Juanatey, Carlos|||0000-0002-4483-9778
  • Revuelta-Evrad, Eva
  • Diaz-Torne, Cesar|||0000-0001-6275-7699
  • Fernández-Espartero, Cruz
  • Pérez-García, Carolina|||0000-0002-6695-6406
  • Torrente-Segarra, Vicenç|||0000-0001-6597-3565
  • Sánchez-Nievas, Ginés
  • Pérez-Sandoval, Trinidad
  • Font-Ugalde, Pilar|||0000-0002-0811-9079
  • García Vivar, María Luz|||0000-0001-8822-9843
  • Aurrecoechea, Elena|||0000-0001-6789-7236
  • Maiz-Alonso, Olga
  • Valls-García, Ramón
  • Miranda-Filloy, José A.
  • Llorca, Javier|||0000-0001-8569-861X
  • Castañeda, Santos|||0000-0002-7748-853X
  • Gonzalez-Gay, MA.|||0000-0002-7924-7406
Objective: Since obesity has been associated with a higher inflammatory burden and worse response to therapy in patients with chronic inflammatory rheumatic diseases (CIRD), we aimed to confirm the potential association between body mass index (BMI) and disease activity in a large series of patients with CIRDs included in the Spanish CARdiovascular in rheuMAtology (CARMA) registry. Methods: Baseline data analysis of patients included from the CARMA project, a 10-year prospective study of patients with rheumatoid arthritis (RA), ankylosing spondylitis (AS), and psoriatic arthritis (PsA) attending outpatient rheumatology clinics from 67 Spanish hospitals. Obesity was defined when BMI (kg/m 2) was.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Influence of MUC5B gene on antisynthetase syndrome

  • López-Mejías, Raquel|||0000-0003-0548-2689
  • Remuzgo-Martínez, Sara|||0000-0003-4455-7241
  • Genre, Fernanda|||0000-0003-3612-1448
  • Pulito-Cueto, Verónica|||0000-0002-3534-8467
  • Fernández Rozas, Sonia María
  • Llorca, Javier|||0000-0001-8569-861X
  • Iturbe, David|||0000-0002-5241-266X
  • Mora Cuesta, Víctor Manuel|||0000-0002-8161-0462
  • Ortego-Centeno, Norberto|||0000-0003-2325-0937
  • Gómez, Nair Pérez
  • Mera-Varela, Antonio
  • Martínez Barrio, Julia
  • López Longo, Francisco Javier
  • Mijares, Verónica
  • Lera-Gómez, Leticia
  • Usetti, María Piedad
  • Laporta, Rosalía
  • Pérez González, Virginia Luz
  • Gafas, Alicia De Pablo
  • Alfranca González, María Aránzazu
  • Calvo Alén, Jaime|||0000-0001-9378-8412
  • Romero-Bueno, Fredeswinda
  • Sánchez Pernaute, Olga
  • Nuno, Laura
  • Bonilla, Gema
  • Balsa, Alejandro|||0000-0001-8070-7062
  • Hernández-González, Fernanda
  • Grafia, Ignacio
  • Prieto-González, Sergio|||0000-0003-3179-597X
  • Narváez, Javier|||0000-0002-1614-8064
  • Trallero Araguás, Ernesto|||0000-0003-3365-4521
  • Selva O'Callaghan, Albert|||0000-0003-2823-9761
  • Gualillo, Oreste|||0000-0002-7154-1328
  • Castañeda, Santos|||0000-0002-7748-853X
  • Cavagna, Lorenzo|||0000-0003-3292-1528
  • Cifrián, José Manuel|||0000-0003-3682-0142
  • Gonzalez-Gay, MA.|||0000-0002-7924-7406
MUC5B rs35705950 (G/T) is strongly associated with idiopathic pulmonary fibrosis (IPF) and also contributes to the risk of interstitial lung disease (ILD) in rheumatoid arthritis (RA-ILD) and chronic hypersensitivity pneumonitis (CHP). Due to this, we evaluated the implication of MUC5B rs35705950 in antisynthetase syndrome (ASSD), a pathology characterised by a high ILD incidence. 160 patients with ASSD (142 with ILD associated with ASSD [ASSD-ILD+]), 232 with ILD unrelated to ASSD (comprising 161 IPF, 27 RA-ILD and 44 CHP) and 534 healthy controls were genotyped. MUC5B rs35705950 frequency did not significantly differ between ASSD-ILD+ patients and healthy controls nor when ASSD patients were stratified according to the presence/absence of anti Jo-1 antibodies or ILD. No significant differences in MUC5B rs35705950 were also observed in ASSD-ILD+ patients with a usual interstitial pneumonia (UIP) pattern when compared to those with a non-UIP pattern. However, a statistically significant decrease of MUC5B rs35705950 GT, TT and T frequencies in ASSD-ILD+ patients compared to patients with ILD unrelated to ASSD was observed. In summary, our study does not support a role of MUC5B rs35705950 in ASSD. It also indicates that there are genetic differences between ILD associated with and that unrelated to ASSD.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

A TNFSF13B functional variant is not involved in systemic sclerosis and giant cell arteritis susceptibility

  • González-Serna, David
  • Carmona, Elio G.
  • Ortego-Centeno, Norberto|||0000-0003-2325-0937
  • Simeón-Aznar, Carmen Pilar|||0000-0003-3390-9029
  • Solans, Roser|||0000-0002-0058-1293
  • Hernández Rodríguez, José|||0000-0002-2357-2015
  • Tolosa, Carlos
  • Castañeda, Santos|||0000-0002-7748-853X
  • Narváez, Javier|||0000-0002-1614-8064
  • Martinez-Valle, Ferran
  • Witte, Torsten
  • Neumann, Thomas
  • Holle, Julia
  • Beretta, Lorenzo|||0000-0002-6529-6258
  • Boiardi, Luigi
  • Emmi, Giacomo|||0000-0001-9575-8321
  • Cimmino, Marco Amedeo|||0000-0002-6956-7860
  • Vaglio, Augusto
  • Herrick, Ariane|||0000-0003-4941-7926
  • Denton, Christopher P.
  • Salvarani, Carlo|||0000-0001-5426-5133
  • Cid, María Cinta|||0000-0002-4730-0938
  • Morgan, Ann W.
  • Fonseca, Carmen
  • Gonzalez-Gay, MA.|||0000-0002-7924-7406
  • Martín, Javier|||0000-0002-2202-0622
  • Márquez, Ana|||0000-0001-9913-7688
The TNFSF13B (TNF superfamily member 13b) gene encodes BAFF, a cytokine with a crucial role in the differentiation and activation of B cells. An insertion-deletion variant (GCTGT→A) of this gene, leading to increased levels of BAFF, has been recently implicated in the genetic predisposition to several autoimmune diseases, including multiple sclerosis, systemic lupus erythematosus, and rheumatoid arthritis. Based on the elevated levels of this cytokine found in patients with giant cell arteritis (GCA) and systemic sclerosis (SSc), we aimed to assess whether this functional variant also represents a novel genetic risk factor for these two disorders. A total of 1,728 biopsy-proven GCA patients from 4 European cohorts, 4,584 SSc patients from 3 European cohorts and 5,160 ethnically-matched healthy controls were included in the study. The single nucleotide polymorphism (SNP) rs374039502, which colocalizes with the genetic variant previously implicated in autoimmunity, was genotyped using a custom TaqMan assay. First, association analysis was conducted in each independent cohort using χ2 test in Plink (v1.9). Subsequently, different case/control sets were meta-analyzed by the inverse variance method. No statistically significant differences were found when allele distributions were compared between cases and controls for any of the analyzed cohorts. Similarly, combined analysis of the different sets evidenced a lack of association of the rs374039502 variant with GCA (P = 0.421; OR (95% CI) = 0.92 (0.75-1.13)) and SSc (P = 0.500; OR (95% CI) = 1.05 (0.91-1.22)). The stratified analysis considering the main clinical subphenotypes of these diseases yielded similar negative results. Our data suggest that the TNFSF13B functional variant does not contribute to the genetic network underlying GCA and SSc.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

The synovial and blood monocyte DNA methylomes mirror prognosis, evolution, and treatment in early arthritis

  • de la Calle-Fabregat, Carlos|||0000-0002-3026-3069
  • Rodríguez-Ubreva, Javier|||0000-0003-4707-4536
  • Ciudad, Laura|||0000-0002-5219-6792
  • Ramírez, Julio
  • Celis, Raquel|||0000-0002-5096-4532
  • Azuaga, Ana Belén
  • Cuervo, Andrea
  • Graell, Eduard|||0000-0002-4210-2721
  • Pérez-García, Carolina|||0000-0002-6695-6406
  • Diaz-Torne, Cesar|||0000-0001-6275-7699
  • Salvador, Georgina
  • Gómez-Puerta, Jose A.|||0000-0001-8177-702X
  • Haro, Isabel|||0000-0001-8677-2340
  • Sanmartí, Raimon|||0000-0002-8864-3806
  • Cañete, Juan D.|||0000-0003-2606-0573
  • Ballestar, Esteban|||0000-0002-1400-2440
Identifying predictive biomarkers at early stages of inflammatory arthritis is crucial for starting appropriate therapies to avoid poor outcomes. Monocytes (MOs) and macrophages, largely associated with arthritis, are contributors and sensors of inflammation through epigenetic modifications. In this study, we investigated associations between clinical features and DNA methylation in blood and synovial fluid (SF) MOs in a prospective cohort of patients with early inflammatory arthritis. DNA methylation profiles of undifferentiated arthritis (UA) blood MOs exhibited marked alterations in comparison with those from healthy donors. We identified additional differences both in blood and SF MOs after comparing patients with UA grouped by their future outcomes, i.e., good versus poor. Patient profiles in subsequent visits revealed a reversion toward a healthy level in both groups, those requiring disease-modifying antirheumatic drugs and those who remitted spontaneously. Changes in disease activity between visits also affected DNA methylation, which was partially concomitant in the SF of UA and in blood MOs of patients with rheumatoid arthritis. Epigenetic similarities between arthritis types allow a common prediction of disease activity. Our results constitute a resource of DNA methylation-based biomarkers of poor prognosis, disease activity, and treatment efficacy for the personalized clinical management of early inflammatory arthritis.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Methylome and transcriptome profiling of giant cell arteritis monocytes reveals novel pathways involved in disease pathogenesis and molecular response to glucocorticoids

  • Estupiñán-Moreno, Elkyn|||0000-0002-5818-4389
  • Ortiz-Fernández, Lourdes|||0000-0002-0247-4280
  • Li, Tianlu|||0000-0001-7152-4870
  • Hernández Rodríguez, José|||0000-0002-2357-2015
  • Ciudad, Laura|||0000-0002-5219-6792
  • Andrés-León, Eduardo|||0000-0002-0621-9914
  • Terron-Camero, Laura Carmen
  • Prieto-González, Sergio|||0000-0003-3179-597X
  • Espígol Frigolé, Georgina|||0000-0002-8299-0209
  • Cid, María Cinta|||0000-0002-4730-0938
  • Márquez, Ana|||0000-0001-9913-7688
  • Ballestar, Esteban|||0000-0002-1400-2440
  • Martín, Javier|||0000-0002-2202-0622
Objectives Giant cell arteritis (GCA) is a complex systemic vasculitis mediated by the interplay between both genetic and epigenetic factors. Monocytes are crucial players of the inflammation occurring in GCA. Therefore, characterisation of the monocyte methylome and transcriptome in GCA would be helpful to better understand disease pathogenesis. Methods We performed an integrated epigenome-and transcriptome-wide association study in CD14+ monocytes from 82 patients with GCA, cross-sectionally classified into three different clinical statuses (active, in remission with or without glucocorticoid (GC) treatment), and 31 healthy controls. Results We identified a global methylation and gene expression dysregulation in GCA monocytes. Specifically, monocytes from active patients showed a more proinflammatory phenotype compared with healthy controls and patients in remission. In addition to inflammatory pathways known to be involved in active GCA, such as response to IL-6 and IL-1, we identified response to IL-11 as a new pathway potentially implicated in GCA. Furthermore, monocytes from patients in remission with treatment showed downregulation of genes involved in inflammatory processes as well as overexpression of GC receptor-target genes. Finally, we identified changes in DNA methylation correlating with alterations in expression levels of genes with a potential role in GCA pathogenesis, such as ITGA7 and CD63, as well as genes mediating the molecular response to GC, including FKBP5, ETS2, ZBTB16 and ADAMTS2. Conclusion Our results revealed profound alterations in the methylation and transcriptomic profiles of monocytes from GCA patients, uncovering novel genes and pathways involved in GCA pathogenesis and in the molecular response to GC treatment.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Tocilizumab in refractory Caucasian Takayasu's arteritis, a multicenter study of 54 patients and literature review

  • Prieto-Peña, Diana
  • Bernabeu, Pilar
  • Vela, Paloma|||0000-0001-8566-5172
  • Narváez, Javier|||0000-0002-1614-8064
  • Fernández-López, Jesús C.
  • Freire-González, Mercedes
  • González-Álvarez, Beatriz
  • Solans, Roser|||0000-0002-0058-1293
  • Callejas Rubio, Jose Luis|||0000-0002-1653-0087
  • Ortego-Centeno, Norberto|||0000-0003-2325-0937
  • Fernández-Díaz, Carlos
  • Rubio, Esteban
  • García-Morillo, Salvador
  • Minguez, Mauricio
  • Fernández-Carballido, Cristina|||0000-0002-0910-4944
  • Miguel, Eugenio de|||0000-0001-5146-1964
  • Melchor, Sheila
  • Salgado, Eva
  • Bravo, Beatriz
  • Romero-Yuste, Susana
  • Salvatierra, Juan
  • Hidalgo, Cristina
  • Manrique, Sara
  • Romero-Gómez, Carlos
  • Moya, Patricia|||0000-0001-8339-5420
  • Álvarez-Rivas, Noelia
  • Mendizabal, Javier
  • Ortiz Sanjuán, Francisco
  • Pérez de Pedro, Iván
  • Alonso-Valdivielso, José L.|||0000-0002-1862-6883
  • Perez-Sanchez, Laura
  • Roldán, Rosa
  • Fernandez-Llanio, Nagore
  • Gómez de la Torre, Ricardo
  • Suarez, Silvia
  • Montesa Cabrera, María Jesús
  • Delgado Sánchez, Mónica
  • Loricera, Javier|||0000-0003-4754-0277
  • Atienza-Mateo, Belén|||0000-0001-7119-0786
  • Castañeda, Santos|||0000-0002-7748-853X
  • Gonzalez-Gay, MA.|||0000-0002-7924-7406
  • Blanco, Ricardo|||0000-0003-2344-2285
Objective: To assess the efficacy and safety of tocilizumab (TCZ) in Caucasian patients with refractory Takayasu's arteritis (TAK) in clinical practice. Methods: A multicenter study of Caucasian patients with refractory TAK who received TCZ. The outcome variables were remission, glucocorticoid-sparing effect, improvement in imaging techniques, and adverse events. A comparative study between patients who received TCZ as monotherapy (TCZ) and combined with conventional disease modifying anti-rheumatic drugs (cDMARDs) (TCZ) was performed. Results: The study comprised 54 patients (46 women/8 men) with a median [interquartile range (IQR)] age of 42.0 (32.5-50.5) years. TCZ was started after a median (IQR) of 12.0 (3.0-31.5) months since TAK diagnosis. Remission was achieved in 12/54 (22.2%), 19/49 (38.8%), 23/44 (52.3%), and 27/36 (75%) patients at 1, 3, 6, and 12 months, respectively. The prednisone dose was reduced from 30.0 mg/day (12.5-50.0) to 5.0 (0.0-5.6) mg/day at 12 months. An improvement in imaging findings was reported in 28 (73.7%) patients after a median (IQR) of 9.0 (6.0-14.0) months. Twenty-three (42.6%) patients were on TCZ and 31 (57.4%) on TCZ: MTX (n = 28), cyclosporine A (n = 2), azathioprine (n = 1). Patients on TCZ were younger [38.0 (27.0-46.0) versus 45.0 (38.0-57.0)] years; difference (diff) [95% confidence interval (CI) = -7.0 (-17.9, -0.56] with a trend to longer TAK duration [21.0 (6.0-38.0) versus 6.0 (1.0-23.0)] months; diff 95% CI = 15 (-8.9, 35.5), and higher c-reactive protein [2.4 (0.7-5.6) versus 1.3 (0.3-3.3)] mg/dl; diff 95% CI = 1.1 (-0.26, 2.99). Despite these differences, similar outcomes were observed in both groups (log rank p = 0.862). Relevant adverse events were reported in six (11.1%) patients, but only three developed severe events that required TCZ withdrawal. Conclusion: TCZ in monotherapy, or combined with cDMARDs, is effective and safe in patients with refractory TAK of Caucasian origin.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Complement component C4 structural variation and quantitative traits contribute to sex-biased vulnerability in systemic sclerosis

  • Kerick, Martin|||0000-0002-6298-4514
  • Acosta-Herrera, Marialbert|||0000-0002-9868-6535
  • Simeón-Aznar, Carmen Pilar|||0000-0003-3390-9029
  • Callejas Rubio, Jose Luis|||0000-0002-1653-0087
  • Assassi, Shervin|||0000-0002-8059-9978
  • Carreira, Patricia E.|||0000-0001-8279-3806
  • Castellvi, Ivan|||0000-0002-5410-5807
  • Ríos, Raquel
  • García-Portales, Rosa
  • Fernández-Nebro, Antonio|||0000-0002-2962-9844
  • García-Hernández, Francisco Jose|||0000-0002-2600-0485
  • Aguirre, Mª Angeles|||0000-0002-5653-4293
  • Fernández-Gutiérrez, Benjamín
  • Rodriguez-Rodriguez, Luis|||0000-0002-2869-7861
  • García de la Peña-Lefebvre, Paloma
  • Vicente-Rabaneda, Esther Francisca
  • Andréu, José Luis|||0000-0002-6002-1239
  • Fernández de Castro, Mónica
  • López Longo, Francisco Javier
  • Fonollosa Pla, Vicent
  • Guillén-Del-Castillo, Alfredo|||0000-0003-0626-507X
  • Espinosa, Gerard|||0000-0003-1336-0163
  • Tolosa, Carlos
  • Pros, Ana|||0000-0003-0266-0531
  • Beltran Catalan, Emma|||0000-0001-8070-6916
  • Rodríguez-Carballeira, Mónica|||0000-0002-8802-0238
  • Narváez, Javier|||0000-0002-1614-8064
  • Rubio Rivas, Manuel|||0000-0002-9548-1374
  • Ortiz-Santamaría, Vera
  • Madroñero, Ana Belén
  • Gonzalez-Gay, MA.|||0000-0002-7924-7406
  • Díaz, Bernardino
  • Trapiella, Luis
  • Egurbide, María Victoria
  • Fanlo-Mateo, Patricia
  • Sáez-Comet, Luis|||0000-0002-9868-6498
  • Díaz, F.
  • Román-Ivorra, José Andrés
  • Alegre-Sancho, Juan José|||0000-0003-1641-0875
  • Freire, Mercedes
  • Garcia, Francisco J.B.
  • Oreiro, Natividad
  • Witte, Torsten
  • Kreuter, Alexander|||0000-0003-2275-499X
  • Riemekasten, Gabriela
  • Airò, Paolo
  • Magro-Checa, César
  • Voskuyl, A.E.|||0000-0002-9699-1827
  • Vonk, Madelon C.
  • Hesselstrand, Roger
  • Nordin, Annika|||0000-0003-1976-4679
  • Lunardi, Claudio|||0000-0001-6446-2990
  • Gabrielli, Armando
  • Hoffmann-Vold, A.
  • Distler, J.H.W.
  • Padyukov, Leonid|||0000-0003-2950-5670
  • Koeleman, B.P.C.
  • Proudman, Susanna M.
  • Nikpour, Mandana
  • Stevens, W.
  • Zochling, Jane M.
  • Sahhar, Joanne|||0000-0003-4220-2906
  • Roddy, J.
  • Nash, P.
  • Tymms, Kathleen
  • Rischmueller, Maureen
  • Lester, Susan Elizabeth
  • Vigone, Barbara
  • Pers, Jacques-Olivier|||0000-0001-7287-5541
  • Saraux, Alain
  • Devauchelle-Pensec, Valérie
  • Cornec, Divi|||0000-0002-9159-702X
  • Jousse-Joulin, Sandrine
  • Lauwerys, Bernard
  • Ducreux, Julie
  • Maudoux, Anne-Lise
  • Vasconcelos, Carlos
  • Tavares, Ana
  • Neves, Esmeralda
  • Faria, Raquel
  • Brandão, Mariana
  • Campar, Ana
  • Marinho, António
  • Farinha, Fátima
  • Almeida, Isabel
  • Blanco, Ricardo|||0000-0003-2344-2285
  • Corrales Martínez, Alfonso
  • Cervera, Ricard
  • Rodríguez-Pintó, Ignasi
  • Lories, Rik
  • De Langhe, Ellen|||0000-0002-4045-2146
  • Belz, Doreen
  • Baerlecken, Niklas
  • Stummvoll, Georg
  • Zauner, Michael
  • Lehner, Michaela
  • Collantes Estevéz, Eduardo|||0000-0002-7647-6289
  • Ortega Castro, Rafaela|||0000-0002-7552-3469
  • Escudero Contreras, Alejandro|||0000-0001-5891-5527
  • Castro-Villegas, Ma Carmen
  • Fernández Roldán, María Concepción
  • Ortego-Centeno, Norberto|||0000-0003-2325-0937
  • Raya, Enrique
  • Jiménez Moleón, Inmaculada
  • de Ramon, Enrique
  • Díaz Quintero, Isabel
  • Meroni, Pier Luigi|||0000-0002-3394-1451
  • Gerosa, Maria|||0000-0001-5241-5847
  • Schioppo, Tommaso|||0000-0001-8359-5131
  • Artusi, Carolina
  • Chizzolini, Carlo
  • Zuber, Aleksandra
  • Wynar, Donatienne
  • Kovács, Laszló
  • Balog, Attila
  • Deák, Magdolna
  • Bocskai, Márta
  • Dulic, Sonja
  • Kádár, Gabriella
  • Hiepe, Falk|||0000-0003-3584-5292
  • Gerl, Velia
  • Thiel, Silvia
  • rodriguez Maresca, Manuel
  • López-Berrio, Antonio
  • Aguilar-Quesada, Rocío|||0000-0003-3125-6634
  • Navarro-Linares, Héctor
  • Hunzelmann, Nicolas
  • Moroncini, Gianluca|||0000-0002-0380-0105
  • de Vries-Bouwstra, Jeska K.
  • Orozco, Gisela|||0000-0002-3479-0448
  • Barton, Anne|||0000-0003-3316-2527
  • Herrick, Ariane|||0000-0003-4941-7926
  • Terao, Chikashi|||0000-0002-6452-4095
  • Allanore, Yannick|||0000-0002-6149-0002
  • Fonseca, Carmen
  • Alarcón-Riquelme, Marta E.|||0000-0002-7632-4154
  • Radstake, Timothy R.D.J.
  • Beretta, Lorenzo|||0000-0002-6529-6258
  • Denton, Christopher P.
  • Mayes, Maureen D.|||0000-0001-5070-2535
  • Martín, Javier|||0000-0002-2202-0622
Copy number (CN) polymorphisms of complement C4 play distinct roles in many conditions, including immune-mediated diseases. We investigated the association of C4 CN with systemic sclerosis (SSc) risk. Imputed total C4, C4A, C4B, and HERV-K CN were analyzed in 26,633 individuals and validated in an independent cohort. Our results showed that higher C4 CN confers protection to SSc, and deviations from CN parity of C4A and C4B augmented risk. The protection contributed per copy of C4A and C4B differed by sex. Stronger protection was afforded by C4A in men and by C4B in women. C4 CN correlated well with its gene expression and serum protein levels, and less C4 was detected for both in SSc patients. Conditioned analysis suggests that C4 genetics strongly contributes to the SSc association within the major histocompatibility complex locus and highlights classical alleles and amino acid variants of HLA-DRB1 and HLA-DPB1 as C4-independent signals.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Tocilizumab in visual involvement of giant cell arteritis, a multicenter study of 471 patients

  • Loricera, Javier|||0000-0003-4754-0277
  • Castañeda, Santos|||0000-0002-7748-853X
  • Moriano, Clara
  • Narváez, Javier|||0000-0002-1614-8064
  • Aldasoro, Vicente
  • Maiz, Olga|||0000-0003-2900-9511
  • Melero-González, Rafael|||0000-0002-7967-351X
  • Villa, Ignacio
  • Vela, Paloma|||0000-0001-8566-5172
  • Romero-Yuste, Susana
  • Callejas Rubio, Jose Luis|||0000-0002-1653-0087
  • Miguel, Eugenio de|||0000-0001-5146-1964
  • Galíndez Agirregoikoa, Eva
  • Sivera, Francisca|||0000-0002-3414-1667
  • Fernández-López, Jesús C.
  • Galisteo-Lencastre, Carlos|||0000-0003-3619-3185
  • Ferraz-Amaro, Iván|||0000-0003-0197-5267
  • Sánchez Martín, Julio
  • Sánchez Bilbao, Lara
  • Calderón-Goercke, Mónica
  • Casado, Alfonso
  • Hernández, José L.
  • Gonzalez-Gay, MA.|||0000-0002-7924-7406
  • Blanco, Ricardo|||0000-0003-2344-2285
Visual involvement is the most feared complication of giant cell arteritis (GCA). Information on the efficacy of tocilizumab (TCZ) for this complication is scarce and controversial. We assessed a wide series of GCA treated with TCZ, to evaluate its role in the prevention of new visual complications and its efficacy when this manifestation was already present before the initiation of TCZ. This is an observational multicenter study of patients with GCA treated with TCZ. Patients were divided into two subgroups according to the presence or absence of visual involvement before TCZ onset. Visual manifestations were classified into the following categories: transient visual loss (TVL), permanent visual loss (PVL), diplopia, and blurred vision. Four hundred seventy-one GCA patients (mean age, 74 ± 9 years) were treated with TCZ. Visual manifestations were observed in 122 cases (26%), of which 81 were present at TCZ onset: PVL (n = 60; unilateral/bilateral: 48/12), TVL (n = 17; unilateral/bilateral: 11/6), diplopia (n = 2), and blurred vision (n = 2). None of the patients without previous visual involvement or with TVL had new episodes after initiation of TCZ, while only 11 out of 60 (18%) patients with PVL experienced some improvement. The two patients with diplopia and one of the two patients with blurred vision improved. TCZ may have a protective effect against the development of visual complications or new episodes of TVL in GCA. However, once PVL was established, only a few patients improved.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

The comparative responsiveness of Hospital Universitario Princesa Index and other composite indices for assessing rheumatoid arthritis activity

  • González-Álvaro, Isidoro
  • Castrejón, Isabel
  • Carmona, Loreto
  • Casado, Enrique|||0000-0001-8839-6430
  • García Gómez, M. C.
  • Gómez Centeno, E.
  • Gómez Vaquero, Carmen
  • Gratacós, Jordi|||0000-0003-4007-4103
  • Larrosa Padro, M.
  • Sanmartí, Raimon|||0000-0002-8864-3806
  • Tena Marsá, X.
  • Valls, M.
  • Diaz-Torne, Cesar|||0000-0001-6275-7699
  • Juanola, Xavier|||0000-0001-5998-6300
  • Laiz, Ana|||0000-0002-2820-4801
To evaluate the responsiveness in terms of correlation of the Hospital Universitario La Princesa Index (HUPI) comparatively to the traditional composite indices used to assess disease activity in rheumatoid arthritis (RA), and to compare the performance of HUPI-based response criteria with that of the EULAR response criteria. Secondary data analysis from the following studies: ACT-RAY (clinical trial), PROAR (early RA cohort) and EMECAR (pre-biologic era long term RA cohort). Responsiveness was evaluated by: 1) comparing change from baseline (Δ) of HUPI with Δ in other scores by calculating correlation coefficients; 2) calculating standardised effect sizes. The accuracy of response by HUPI and by EULAR criteria was analyzed using linear regressions in which the dependent variable was change in global assessment by physician (ΔGDA-Phy). ΔHUPI correlation with change in all other indices ranged from 0.387 to 0.791); HUPI's standardized effect size was larger than those from the other indices in each database used. In ACT-RAY, depending on visit, between 65 and 80% of patients were equally classified by HUPI and EULAR response criteria. However, HUPI criteria were slightly more stringent, with higher percentage of patients classified as non-responder, especially at early visits. HUPI response criteria showed a slightly higher accuracy than EULAR response criteria when using ΔGDA-Phy as gold standard. HUPI shows good responsiveness in terms of correlation in each studied scenario (clinical trial, early RA cohort, and established RA cohort). Response criteria by HUPI seem more stringent than EULAR's.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

GWAS for systemic sclerosis identifies multiple risk loci and highlights fibrotic and vasculopathy pathways

  • López-Isac, Elena|||0000-0001-8806-5148
  • Acosta-Herrera, Marialbert|||0000-0002-9868-6535
  • Kerick, Martin|||0000-0002-6298-4514
  • Assassi, Shervin|||0000-0002-8059-9978
  • Satpathy, Ansuman|||0000-0002-5167-537X
  • Granja, Jeffrey
  • Mumbach, Maxwell|||0000-0002-5570-6663
  • Beretta, Lorenzo|||0000-0002-6529-6258
  • Simeón-Aznar, Carmen Pilar|||0000-0003-3390-9029
  • Carreira, Patricia E.|||0000-0001-8279-3806
  • Ortego-Centeno, Norberto|||0000-0003-2325-0937
  • Castellvi, Ivan|||0000-0002-5410-5807
  • Bossini-Castillo, Lara|||0000-0002-5471-5824
  • Carmona, F. David|||0000-0002-1427-7639
  • Orozco, Gisela|||0000-0002-3479-0448
  • Hunzelmann, Nicolas
  • Distler, Jörg|||0000-0001-7408-9333
  • Franke, Andre|||0000-0003-1530-5811
  • Lunardi, Claudio|||0000-0001-6446-2990
  • Moroncini, Gianluca|||0000-0002-0380-0105
  • Gabrielli, Armando
  • de Vries-Bouwstra, Jeska
  • Wijmenga, Cisca|||0000-0002-5635-1614
  • Koeleman, Bobby|||0000-0001-7749-182X
  • Nordin, Annika|||0000-0003-1976-4679
  • Padyukov, Leonid|||0000-0003-2950-5670
  • Hoffmann-Vold, A.M.|||0000-0001-6467-7422
  • Lie, Benedicte A.|||0000-0002-1159-7004
  • Ríos, Raquel
  • Callejas Rubio, Jose Luis|||0000-0002-1653-0087
  • Vargas-Hitos, José Antonio|||0000-0002-0596-8710
  • García-Portales, Rosa
  • Camps, María Teresa
  • Fernández-Nebro, Antonio|||0000-0002-2962-9844
  • González-Escribano, Maria Francisca
  • García-Hernández, Francisco Jose|||0000-0002-2600-0485
  • Castillo, María Jesús
  • Aguirre, Mª Angeles|||0000-0002-5653-4293
  • Gómez-Gracia, Inmaculada
  • Fernández-Gutiérrez, B.|||0000-0002-6126-8786
  • Rodríguez-Rodríguez, L.
  • García de la Peña, Paloma|||0000-0001-6586-6903
  • Vicente-Rabaneda, Esther Francisca
  • Andréu, José Luis|||0000-0002-6002-1239
  • Fernández de Castro, Mónica
  • López Longo, Francisco Javier
  • Martínez, Lina
  • Fonollosa, Vicenç
  • Guillén, Alfredo Chávez
  • Espinosa, Gerard|||0000-0003-1336-0163
  • Tolosa Vilella, Carles|||0000-0002-3379-4412
  • Pros, Ana|||0000-0003-0266-0531
  • Rodríguez-Carballeira, M.
  • Narváez, Francisco J.
  • Rubio Rivas, Manuel|||0000-0002-9548-1374
  • Ortiz-Santamaría, None
  • Madroñero, A.B.
  • Gonzalez-Gay, MA.|||0000-0002-7924-7406
  • Díaz, Bernardino
  • Trapiella, L.
  • Sousa, A.
  • Egurbide, María Victoria
  • Fanlo-Mateo, P.
  • Sáez-Comet, Luis|||0000-0002-9868-6498
  • Díaz, F.
  • Hernández, None
  • Beltrán, E.
  • Román-Ivorra, J.A.
  • Grau, E.
  • Alegre-Sancho, Juan José|||0000-0003-1641-0875
  • Freire, M.
  • Blanco-García, F.J.|||0000-0001-9821-7635
  • Oreiro, N.
  • Witte, Torsten
  • Kreuter, A.
  • Riemekasten, G.|||0000-0002-5406-2464
  • Airò, Paolo
  • Magro-Checa, César
  • Voskuyl, A.E.|||0000-0002-9699-1827
  • Vonk, Madelon C.
  • Hesselstrand, Roger
  • Proudman, Susanna
  • Stevens, Wendy
  • Nikpour, Mandana
  • Zochling, Jane M.
  • Sahhar, Joanne|||0000-0003-4220-2906
  • Roddy, Janet
  • Nash, Peter
  • Tymms, Kathleen
  • Rischmueller, Maureen
  • Lester, S.
  • Vyse, Timothy|||0000-0003-1123-1464
  • Herrick, Ariane|||0000-0003-4941-7926
  • Worthington, Jane
  • Denton, Christopher P.
  • Allanore, Yannick|||0000-0002-6149-0002
  • Brown, Matthew A.|||0000-0003-0538-8211
  • Radstake, Timothy R. D. J.
  • Fonseca, Carmen
  • Chang, Howard Y.
  • Mayes, Maureen D.|||0000-0001-5070-2535
  • Martín, Javier|||0000-0002-2202-0622
Systemic sclerosis (SSc) is an autoimmune disease that shows one of the highest mortality rates among rheumatic diseases. We perform a large genome-wide association study (GWAS), and meta-analysis with previous GWASs, in 26,679 individuals and identify 27 independent genome-wide associated signals, including 13 new risk loci. The novel associations nearly double the number of genome-wide hits reported for SSc thus far. We define 95% credible sets of less than 5 likely causal variants in 12 loci. Additionally, we identify specific SSc subtype-associated signals. Functional analysis of high-priority variants shows the potential function of SSc signals, with the identification of 43 robust target genes through HiChIP. Our results point towards molecular pathways potentially involved in vasculopathy and fibrosis, two main hallmarks in SSc, and highlight the spectrum of critical cell types for the disease. This work supports a better understanding of the genetic basis of SSc and provides directions for future functional experiments.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Synovial Immunohistological Biomarkers of the Classification of Undifferentiated Arthritis Evolving to Rheumatoid or Psoriatic Arthritis

  • Cuervo, Andrea
  • Celis, Raquel
  • Julia Cano, Antonio
  • Usategui, Alicia
  • Faré, Regina
  • Ramírez, Julio
Artritis psoriàsica; Artritis reumatoide; Sinovitis, Artritis psoriásica; Artritis reumatoide; Sinovitis, Psoriatic arthritis; Rheumatoid arthritis; Synovitis, Background: Undifferentiated arthritis (UA) is defined as an inflammatory arthritis that does not fulfill criteria for a definite diagnosis. Delay in reaching a specific diagnostic and therapy may lead to impaired functional outcomes. Our aim was to identify synovial biomarkers associated with definitive diagnostic classification in patients with UA. Methods: DMARD-naïve UA patients with available initial synovial tissue (ST) and a final diagnosis of rheumatoid arthritis (RA) or psoriatic arthritis (PsA) during follow-up were included and compared with patients with well-defined disease (RA or PsA). Clinical, arthroscopic, and pathological data were compared between groups. Pathology included quantitative immunohistochemical (IHC) analysis of cell types and human interferon-regulated MxA. Principal component analysis (PCA) was performed to extract disease patterns. Results: One hundred and five patients were included: 31 patients with DMARD-naïve UA (19 evolving to RA and 12 to PsA during a median follow up of 7 years), 39 with established RA, and 35 with established PsA. ST from the UA group showed higher macrophage density compared with the established RA and PsA groups. Patients with UA evolving to RA (UA-RA) showed higher MxA expression and CD3+ T-cell density compared with established RA. UA patients evolving to PsA (UA-PsA) showed increased vascularity and lining synovial fibroblast density compared with established PsA. Synovitis of UA-PsA patients showed more mast cells and lining fibroblasts compared with UA-RA. No between-group differences in local or systemic inflammation markers were found. Conclusions: Our results show differences in the cellular composition of UA synovium compared with RA and PsA, with higher density of the cellular infiltrate in the UA groups. Initial expression of the interferon inducible gene MxA could be a biomarker of progression to RA, while higher mast cell and fibroblastic density may be associated with PsA progression., This research was supported by Instituto de Salud Carlos III (ISCIII) through the PI14/00785 and RD16/0012 RETICS program, cofinanced by the European Regional Development Fund (FEDER), “Una manera de hacer Europa”. AC also received grants from Sociedad Española de Reumatología (BECA FER-2015), Hospital Clinic de Barcelona, Projectes Fi de Residencia: Premis Emili Letang, and from Sociedad Catalana de Reumatología.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Role of VEGF Polymorphisms in the Susceptibility and Severity of Interstitial Lung Disease

  • Remuzgo-Martínez, Sara
  • Genre, Fernanda
  • Pulito-Cueto, Verónica
  • Atienza-Mateo, Belén
  • Mora Cuesta, Víctor Manuel
  • Iturbe Fernández, David
  • Berastegui Garcia, Cristina
Biomarker; Interstitial lung disease; Vascular endothelial growth factor, Biomarcador; Malaltia pulmonar intersticial; Factor de creixement endotelial vascular, Biomarcador; Enfermedad pulmonar intersticial; Factor de crecimiento vascular endotelial, The search for biomarkers that can help to establish an early diagnosis and prognosis of interstitial lung disease (ILD) is of potential interest. VEGF polymorphisms have been implicated in the development of several lung disorders. Consequently, we assessed, for the first time, the role of VEGF polymorphisms in the susceptibility and severity of ILD. A total of 436 Caucasian ILD patients (244 with idiopathic interstitial pneumonias (IIPs) and 192 with non-IIP) and 536 ethnically-matched healthy controls were genotyped for VEGF rs833061, rs1570360, rs2010963, rs3025020, and rs3025039 polymorphisms by TaqMan assays. Pulmonary function tests were collected from all the patients. VEGF serum levels were determined by ELISA in a subgroup of patients. No VEGF genotype, allele, carrier, or haplotype differences were found between ILD patients and controls as well as between IIP and non-IIP patients. However, an association of rs1570360 with IIP in women and also with lung function in IIP patients was found. None of the VEGF polymorphisms were associated with VEGF levels. In conclusion, our results suggest that VEGF does not seem to play a relevant role in ILD, although rs1570360 may influence the severity of ILD in women and a worse outcome in IIP patients., This research was partially supported by a grant from Spanish Society of Pulmonology and Thoracic Surgery (SEPAR 474-2017). S.R.-M. was supported by funds of the RETICS Program (RD16/0012/0009) from the “Instituto de Salud Carlos III” (ISCIII), co-funded by the European Regional Development Fund. V.P.-C. was supported by a pre-doctoral grant from IDIVAL (PREVAL 18/01). B.A.-M. was recipient of a “López Albo” post-residency program funded by Servicio Cántabro de Salud. L.L.-G. was supported by funds from IDIVAL (INNVAL 20/06). O.G. was beneficiary of a grant funded by Xunta de Galicia, Consellería de Educación, Universidade e Formación Profesional and Consellería de Economía, Emprego e Industria (GAIN), GPC IN607B2019/10. R.L.-M. was a recipient of a Miguel Servet type I program fellowship from the ISCIII, co-funded by the ESF, “Investing in your future” (grant CP16/00033).